{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:36Z","timestamp":1761093156609,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.urolonc.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T01:45:07Z","timestamp":1629942307000},"page":"107.e1-107.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Rikiya","family":"Taoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souhei","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamasa","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsutaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"The Bethesda handbook of clinical oncology","author":"Abraham","key":"10.1016\/j.urolonc.2021.08.002_bib0001"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0002","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u20132019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0005","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0006","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0007","unstructured":"National Cancer Institute Surveillance, Epidemiology and end results program. SEER cancer statistics factsheets: bladder cancer, https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html, [accessed 01 May 2021]."},{"key":"10.1016\/j.urolonc.2021.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0009","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0011","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0012","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.purol.2013.03.003","article-title":"Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease","volume":"23","author":"Masson-Lecomte","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0013","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/cam4.3739","article-title":"Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0014","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3892\/ol.2017.6080","article-title":"Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer","volume":"13","author":"Liu","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/BLC-190238","article-title":"PD-L1\/PD-1 biomarker for metastatic urothelial cancer that progress post-platinum therapy: a systematic review and meta-analysis","volume":"5","author":"Tan","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0016","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/MOU.0000000000000789","article-title":"Bladder sparing landscape for bacillus Calmette-Gu\u00e9rin unresponsive bladder cancer","volume":"30","author":"Soria","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0017","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0022","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0023","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.urolonc.2019.01.002","article-title":"Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions","volume":"37","author":"Burgess","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0024","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","article-title":"Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma","volume":"1","author":"McDaniel","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.08.002_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2019.07.027","article-title":"Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy","volume":"136","author":"Choe","year":"2019","journal-title":"Lung Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:48Z","timestamp":1761042288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1078143921003616"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.08.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}